PuSH - Publikationsserver des Helmholtz Zentrums München

Helm, F.* ; Kammertoens, T.* ; Lehmann, F.M. ; Wilke, A.* ; Bruns, H.* ; Mautner, J. ; Bornkamm, G.W. ; Gerbitz, A.*

Targeting c-MYC with T-cells.

PLoS ONE 8:e77375 (2013)
Verlagsversion Volltext DOI
Open Access Gold
Creative Commons Lizenzvertrag
Over-expression of the proto-oncogene c-MYC is frequently observed in a variety of tumors and is a hallmark of Burkitt´s lymphoma. The fact that many tumors are oncogene-addicted to c-MYC, renders c-MYC a powerful target for anti-tumor therapy. Using a xenogenic vaccination strategy by immunizing C57BL/6 mice with human c-MYC protein or non-homologous peptides, we show that the human c-MYC protein, despite its high homology between mouse and man, contains several immunogenic epitopes presented in the context of murine H2(b) haplotype. We identified an MHC class II-restricted CD4(+) T-cell epitope and therein an MHC class I-restricted CD8(+) T-cell epitope (SSPQGSPEPL) that, after prime/boost immunization, protected up to 25% of mice against a lethal lymphoma challenge. Lymphoma-rejecting animals contained MHC multimer-binding CD8(+) cell within the peripheral blood and displayed in vivo cytolytic activity with specificity for SSPQGSPEPL. Taken together these data suggest that oncogenic c-MYC can be targeted with specific T-cells.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Oncogene Inactivation ; Tissue Microarrays ; Burkitts-lymphoma ; Dendritic Cells ; Cancer ; Antigen ; Immunotherapy ; Differentiation ; Mutations ; Tumors
ISSN (print) / ISBN 1932-6203
Zeitschrift PLoS ONE
Quellenangaben Band: 8, Heft: 10, Seiten: , Artikelnummer: e77375 Supplement: ,
Verlag Public Library of Science (PLoS)
Verlagsort Lawrence, Kan.
Begutachtungsstatus Peer reviewed